What does it mean to call a substance Schedule I while indigenous peoples have used it sacramentally for millennia?

Psilocybin appears in over two hundred species of fungi. When ingested, the body converts it to psilocin, the active compound. Mesoamerican ceremonial use extends back at least two thousand years — possibly far longer. Ethnomycologist R. Gordon Wasson brought it to Western scientific attention in the late 1950s, largely by attending ceremonies he later published about in Life magazine in 1957, with consequences for the healer involved — María Sabina — that were neither sought nor welcome.

DMT (dimethyltryptamine) occurs naturally in dozens of plant species. Some researchers argue it is also produced endogenously in the human brain, though this claim remains contested. When smoked or vaporized, DMT produces one of the most intense altered states known to pharmacology — typically under twenty minutes in duration, routinely described as subjectively timeless. It is also the psychoactive core of ayahuasca, the ceremonial brew of Amazonian peoples, which combines DMT-containing plants with monoamine oxidase inhibitors to achieve oral activation. Ayahuasca ceremonies predate any Western encounter with the Amazon by centuries, possibly millennia.

LSD (lysergic acid diethylamide) was synthesized by Albert Hofmann at Sandoz Laboratories in 1938. Its psychoactive properties were discovered accidentally in 1943. Unlike psilocybin and DMT, it carries no traditional ceremonial history. Yet its effects overlap substantially with both. All three belong to the category of classical psychedelics — or serotonergic hallucinogens — working primarily through agonism at the 5-HT2A receptor, whose exact role in consciousness is still being mapped.

Mescaline, found in peyote and San Pedro cacti, and ibogaine, derived from the African shrub Tabernanthe iboga, complete the major classical psychedelics in current research focus. Each carries a deep indigenous ceremonial context. Each has a distinct pharmacological profile. They are not interchangeable. But they share a chemical and experiential family resemblance strong enough to make them meaningful as a group.

The Controlled Substances Act of 1970 placed all of them in Schedule I — no accepted medical use, high abuse potential. Whatever research had been conducted in the 1950s and 1960s was cut off. An entire field entered what you might call regulatory suspended animation. What followed was not forgetting. It was underground preservation. Researchers, therapists, philosophers, and practitioners continued working in private, building an experiential literature the academy could not officially touch.

When the moratorium began to lift — late 1990s, early 2000s — scientists returned not to nothing but to a vast, unsanctioned archive of human inquiry. That archive was waiting.

What does rigorous methodology look like when the substance you're studying dissolves the boundary between self and cosmos?

Johns Hopkins University established its Center for Psychedelic and Consciousness Research in 2019 — the first research center of its kind at a major American academic medical institution. Its founding was treated as a cultural moment, and correctly so. But the groundwork had been laid over a decade earlier.

In 2006, Roland Griffiths and colleagues published a landmark study in the journal Psychopharmacology. High-dose psilocybin was administered to healthy volunteers in a controlled, supportive setting. Roughly two-thirds of participants rated the experience among the five most spiritually significant of their lives. Some rated it the most significant. At fourteen-month follow-up, the majority reported persisting increases in well-being and positive behavioral change. The study used double-blind conditions and active placebos. It landed in the scientific literature like a stone dropped in still water.

What followed was accumulation. Subsequent Johns Hopkins studies on tobacco addiction found abstinence rates around eighty percent at six-month follow-up. Current pharmacological treatments for nicotine addiction rarely exceed thirty-five percent. Studies on alcohol use disorder, treatment-resistant depression, and major depressive disorder followed — from Hopkins, NYU, Imperial College London, and others — consistently finding effects that outlasted the acute drug experience by weeks, months, sometimes years.

The crucial variable, researchers found, is not simply the molecule. Set and setting — the participant's internal state and external environment — are major determinants of both the character and the therapeutic outcome of the experience. Indigenous ceremonial traditions had encoded this wisdom for generations without the vocabulary of clinical psychology. The formal term now used in research protocols is psychedelic-assisted therapy: the substance as catalyst within a broader therapeutic structure, not as standalone treatment.

What is not yet fully understood is the mechanism. The correlation between mystical experience and therapeutic outcome is robust across multiple studies. But whether the experience works by disrupting rigid neural patterns, through emotional processing, through a genuine shift in the framework of meaning, or some combination — that remains open. Understanding the mechanism matters clinically. It shapes how protocols should be designed, and what preparation and integration actually require.

What exactly is the brain doing when the self disappears?

The most influential neuroscientific framework for understanding psychedelics centers on the default mode network (DMN) — a set of interconnected brain regions active during rest, self-referential thought, mental time travel, and the construction of what we call the autobiographical self. It includes the medial prefrontal cortex, the posterior cingulate cortex, and the angular gyrus. These are the regions that track who you are, where you've been, and where you're going.

Neuroscientist Robin Carhart-Harris and colleagues at Imperial College London used fMRI and MEG brain imaging to show that classical psychedelics reliably suppress DMN activity. The degree of suppression correlates directly with subjective experience intensity — specifically with ego dissolution, the partial or complete breakdown of the felt sense of being a separate, bounded self. This is one of the most consistently reported and most philosophically charged features of high-dose psychedelic experience.

When the DMN quiets, activity elsewhere increases. Regions that do not normally communicate begin to do so. Psychedelics appear to increase neural entropy — the complexity and unpredictability of brain activity. Under their influence, the brain operates in a less constrained, more fluid mode, forming connections between areas that ordinarily maintain functional separation. Carhart-Harris proposed the entropic brain hypothesis: the mind under psychedelics occupies a higher-entropy state than ordinary waking consciousness — closer to dreaming, or to early childhood experience, than to the organized, prediction-generating machine of the adult brain.

What this produces experientially is a dissolution of habitual patterns. Perceptual. Cognitive. Emotional. Self-referential. The rigid narrative structures through which we ordinarily process experience temporarily loosen. This may explain both the therapeutic potential and the profound strangeness simultaneously. The same mechanism that disrupts depressive rumination loops might allow a person to encounter the world as if for the first time.

The word might is doing real work in that sentence. Neuroscience can map the correlates of ego dissolution with increasing precision. Whether those correlates constitute an explanation, or merely a description, is a question that remains genuinely open.

Why does a philosopher writing in 1902 read like a précis of the contemporary research agenda?

William James published The Varieties of Religious Experience in 1902. It remains one of the most sophisticated attempts to take mystical experience seriously as a subject of empirical inquiry. James identified four defining marks of mystical states of consciousness: noetic quality — the sense that genuine knowledge has been received. Ineffability — resistance to ordinary language. Transiency — brief duration. Passivity — the sense that the experience happens to the person, not through them.

Anyone familiar with accounts of high-dose psychedelic experience will recognize this immediately. The overlap is not coincidental.

James himself experimented with nitrous oxide. He was influenced by Benjamin Paul Blood, who had written extensively on the mind-altering properties of anesthesia. He did not live to see LSD or the discovery of psilocybin. But he wrote: "Our normal waking consciousness, rational consciousness as we call it, is but one special type of consciousness, whilst all about it, parted from it by the filmiest of screens, there lie potential forms of consciousness entirely different." Written in 1902. Reads in 2024 as a research mandate.

Aldous Huxley continued the lineage in The Doors of Perception in 1954, documenting his first mescaline experience and proposing the reducing valve theory of consciousness. Ordinary brain function, he argued, acts as a filter — narrowing the totality of possible experience to the thin stream needed for biological survival. Psychedelics temporarily open that valve. Huxley drew explicitly on philosopher Henri Bergson and on a lifetime of studying mystical traditions. Whether the reducing valve is neurologically accurate remains genuinely uncertain. But it captured something phenomenologically precise that millions of readers recognized.

The line from James to Huxley to Griffiths to Carhart-Harris is not merely biographical. It is an intellectual lineage: the conviction that altered states of consciousness are not pathologies to dismiss, or curiosities to catalogue, but data. Important, possibly irreplaceable data about the nature of mind.

The same phenomenology appears in Meister Eckhart, in Rumi, in the Vedantic philosopher Shankara, in the Buddhist philosopher Nagarjuna. Carefully prepared participants in Hopkins trials, lying on a couch with eye masks and gentle music, describe states that bear striking resemblance to what these figures spent their lives articulating. What should we make of that resemblance? The perennial philosophy hypothesis, associated with Huxley, Leibniz, and a long tradition of comparative mystics, holds that these traditions were all describing the same underlying feature of reality. The alternative is that the human brain has a particular mode it can enter — and many roads lead there. What that mode is for has not been answered.

What do you do with a reported experience that neuroscience can correlate but cannot explain?

A large proportion of people who undergo high-dose DMT experiences report encountering autonomous entities — beings that appear to have independent existence, agency, and intent. These entities communicate, often without words. They are consistently described as more real than ordinary reality. Loving, terrifying, alien, and familiar at once.

A large-scale study published in 2019 by Alan Davis, Roland Griffiths, and colleagues at Johns Hopkins surveyed over two thousand DMT users. Nearly half reported encountering some kind of entity. A substantial portion described the encounter among the most meaningful experiences of their lives. Many reported persisting changes in their beliefs about consciousness, death, and the nature of reality. Remarkably, a significant minority of atheists and agnostics reported that the experience had shifted them toward believing in some form of higher power or fundamental consciousness — not through argument, but through apparent encounter.

What are these entities? The intellectually honest answer: unknown.

The naturalistic explanation: they are products of the brain itself — extraordinary creative fictions generated by a mind freed from its ordinary organizational constraints, drawing on deep archetypal structures. The systems that normally distinguish self from other, real from imagined, are temporarily offline. The entities feel real because the apparatus of reality-testing is suspended.

The alternative explanation — held by shamanic traditions across cultures — is that the spirit world is real, navigable, and these entities are its inhabitants.

Rick Strassman conducted the first federally approved clinical research on DMT in the United States in the early 1990s. He began as a materialist neuroscientist. He ended, by his own account, deeply uncertain. His book DMT: The Spirit Molecule (2001) documents his growing discomfort with purely neurological explanations and his inability to dismiss his participants' reports as simple hallucination. Strassman has since proposed that DMT may function as an endogenous psychedelic produced by the pineal gland, facilitating contact with non-material dimensions. This hypothesis is speculative and contested. It has also proven extraordinarily generative.

The entity encounter question has direct implications for the hard problem of consciousness — David Chalmers' formulation of the question of why physical processes give rise to subjective experience at all. If we cannot yet explain why there is something it is like to see red, we are nowhere close to explaining why there is something it is like to feel that you have met beings older than the universe in a room that lasted fifteen minutes.

Who owns knowledge that has been tended for a thousand years?

These substances did not enter human experience through laboratory synthesis or clinical trials. They arrived through centuries — in most cases millennia — of careful, intentional use by indigenous peoples who developed sophisticated frameworks for working with them safely and meaningfully.

Ayahuasca is the clearest case. Combining Banisteriopsis caapi — an MAO inhibitor — with Psychotria viridis — a DMT source — achieves oral psychedelic activity through a synergistic mechanism that required deep observational knowledge to discover. The ceremonial framework surrounding its use encodes clinical wisdom the Western research tradition is only beginning to formalize. The role of the curandero or vegetalista. The use of icaros — healing songs. The dietary and behavioral restrictions of dieta. The integration of experience within a broader cosmological worldview. These are not incidental ritual wrappings. Researchers are increasingly finding they are load-bearing.

The same is true of peyote within the Native American Church, which has used it sacramentally for well over a century, and in Mesoamerican contexts for far longer. And of psilocybin mushrooms within the Mazatec tradition of Oaxaca, where María Sabina practiced the velada — a healing ceremony of considerable complexity — until Wasson's 1957 Life magazine article brought outsiders to her door and ended her ability to practice in peace.

Western researchers and entrepreneurs have benefited substantially from knowledge developed and preserved by communities that faced legal persecution for using their own traditional medicines. The ayahuasca tourism industry, concentrated in cities like Iquitos and throughout the Sacred Valley, has generated both economic opportunity and exploitation. Serious practitioners in the psychedelic renaissance are increasingly engaging with revenue sharing, explicit acknowledgment of indigenous knowledge, and advocacy for indigenous legal rights. The tension between scientific appropriation and cultural respect is real. It is not close to resolved.

There is also a deeper epistemological point. Indigenous traditions do not understand these substances as neurochemical tools. They understand them as mediators of relationship with the living world — plants, animals, ancestors, the intelligence of nature itself. Whether that cosmological framework is literal, metaphorical, or something that Western conceptual categories cannot quite accommodate is a question that deserves serious rather than dismissive engagement.

Where does the genuine promise end and the overclaim begin?

The psychedelic renaissance is not without complications. Intellectual honesty requires naming them.

Integration is the first. Making meaning from, and translating into ordinary life, experiences that are often overwhelming, destabilizing, and resistant to conventional frameworks is not automatic. Research protocols at Johns Hopkins and elsewhere dedicate significant preparation and integration sessions to this work. There is growing evidence that this container is not incidental — it is structurally essential to therapeutic outcomes. Outside clinical trials, many people are using these substances without adequate support. Some of them are struggling. Psychedelic experiences can surface trauma, generate intense confusion, and occasionally produce lasting psychological disturbance — particularly in individuals with personal or family histories of psychosis.

Challenging experiences — in their most extreme form, psychedelic-induced psychological emergencies — are real. The research literature carefully distinguishes between difficult experiences that ultimately prove growth-producing and genuinely harmful outcomes. The risk calculation appears favorable for carefully screened participants in supervised settings. It looks different in their absence.

The second complication is the evidence base itself. Much of the clinical research, though genuinely promising, involves small sample sizes, challenges with blinding — it is difficult to conceal whether someone received a psychedelic or a placebo, since the effects are unmistakable — and relatively short follow-up periods. Larger studies are underway. Phase II and Phase III clinical trials for MDMA in PTSD, psilocybin in depression and addiction, and other compounds are active. But it remains a young science. Some of the more dramatic claims circulating in popular accounts are ahead of what the data actually support.

Third: commercialization. As psychedelic-assisted therapy moves toward mainstream clinical acceptance, significant financial interests have attached themselves to the field. Patent disputes over formulations, therapeutic protocols, and drug delivery mechanisms are already emerging. The risk that a healing modality developed over millennia in indigenous communities, refined through decades of underground therapeutic practice, and now validated by academic research could be captured and commodified by pharmaceutical corporations is not hypothetical. It is already underway. This does not invalidate the medicines. It raises sharp questions about access, cost, and whose framework governs the encounter.

Some truths outlast every age. Some questions survive every attempt to answer them.

The most philosophically significant finding from the contemporary research is also the most difficult to explain: the reliable production of what Griffiths and colleagues describe as mystical-type experiences — unified, deeply felt encounters with what participants consistently describe as ultimate reality, boundless love, or the ground of being — and the correlation of those experiences with lasting positive change.

This finding sits at the intersection of empirical psychology, philosophy of mind, and the oldest questions every mystical tradition in human history has ever asked. William James would have recognized it immediately. So would Meister Eckhart. So would Rumi. So would Shankara and Nagarjuna.

A carefully prepared person ingests four to five grams of psilocybin mushrooms. Lies on a couch. Eye mask on. Gentle music. Trained guide present. What follows bears striking phenomenological resemblance to what those figures spent their lives attempting to describe. The resemblance could mean several things. That these traditions were inducing similar neurochemical states through other means — meditation, fasting, breathwork, physical ordeal — and that the states themselves carry certain invariant features wherever they arise. Or that the meaning carried by these experiences is constructed after the fact, shaped by cultural expectation, and the neurochemical event itself is filtered through existing belief. Or something more radical: that these states provide genuine access to aspects of reality ordinarily inaccessible, and the consistency across cultures reflects the consistency of whatever those aspects are.

None of these explanations has been established. None has been ruled out.

What psychedelics may have contributed, beyond their clinical applications, is a renewed urgency to take the question of consciousness itself seriously. In an intellectual culture that had largely either dismissed consciousness as epiphenomenal or deferred its investigation indefinitely, the spectacle of serious scientists at Johns Hopkins discussing the greatest mystery in science with visible wonder represents something worth attending to.

The ancient and the cutting-edge are not as separate as the modern mind prefers to assume. When a researcher in a Baltimore laboratory publishes a paper on the neurological correlates of self-dissolution, and a Mazatec curandera in Oaxaca prepares mushrooms for a healing ceremony, in the same week — they are engaged, from different directions, with the same territory. Neither has a complete map. Both have been there.